About: Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Sector: Healthcare
Industry: Biotechnology
Latest price: $28.80 (+1.87%)
LKFTNASDAQLakefront Biotherapeutics NV
Loading watchlist status…
Lakefront Biotherapeutics NV share price
LKFT price activity
Last Price
Change (24hr)
USD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
LKFT price performance
4,65%
5D
-1,47%
1M
-2,04%
YTD
-2,04%
1Y
LKFT price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US-NASDAQ rank
N/ASector Rank
N/ALKFT details
quote.marketSignals